Panel Discussion | What is the Future of Software Medical Devices in Cardiology?

Monday, March 10, 2025

9:32 AM – 9:40 AM ET

Panel Moderator(s)

Mona Advani, M.Sc., MBA

Principal Regulatory Consultant
CardioMed Device Consultants
HERNDON, Virginia, United States

Disclosure(s): No financial relationships to disclose
Richard E. Galgon, MD, MS

Principal Consultant
CardioMed Device Consultants, LLC
Waunakee, Wisconsin, United States

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Rafael Beyar, MD, DSc, MPH

Interventional cardiologists and President
Rambam Hospital/ Rambam Friends Organizations
Haifa, Israel

Disclosure(s): Bio-T: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cuspa medical: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); medhub AI: Stock-privately held company (Ongoing)
Chaim Shaul Lotan, MD

Chief Innovation Officer
Hadassah-Hebrew University Medical Center
Jerusalem, Israel

Disclosure(s): No financial relationships to disclose
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

Professor
Johns Hopkins
Reisterstown, Maryland, United States

Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)
Semih Oktay, PhD

President
Cardiomed Device Consultants
Annapolis, Maryland, United States

Disclosure information not submitted.

Disclosure(s):

Mona Advani, M.Sc., MBA: No financial relationships to disclose

Richard E. Galgon, MD, MS: No financial relationships to disclose

Rafael Beyar, MD, DSc, MPH: Bio-T: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cuspa medical: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); medhub AI: Stock-privately held company (Ongoing)

Chaim Shaul Lotan, MD: No financial relationships to disclose

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)